The field of ovarian cancer research is undergoing a profound transformation, driven by significant advancements in personalized medicine and innovative…
Read More
European Commission Approves Keytruda Combination Therapy for PD-L1-Positive Platinum-Resistant Ovarian Cancer
The European Commission (EC) has granted approval for Keytruda (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, as a…
Read More
Corcept’s first-in-class ovarian cancer drug gains FDA approval – Pharmaceutical Technology
Corcept Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for its selective…
Read MoreYOU MAY HAVE MISSED
